Roche Holding AGXSWX:RO -0.29%75 Debt-to-Equity is 0.98 as of Dec. 2025, which is 4% above its 10-year median of 0.94. GuruFocus rates XSWX:RO with a GF Score™ of 75/100 and a GF Value™ of CHF269.24 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 809 Drug Manufacturers companies, Roche Holding AG ranks worse than 85.04% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Roche Holding AG's Debt-to-Equity or its related term are showing as below:
XSWX:RO'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.42 Med: 0.94 Max: 1.33
Current: 0.98
During the past 13 years, the highest Debt-to-Equity Ratio of Roche Holding AG was 1.33. The lowest was 0.42. And the median was 0.94.
XSWX:RO's Debt-to-Equity is ranked worse than 85.04% of 809
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs XSWX:RO: 0.98
Roche Holding AG (XSWX:RO) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Roche Holding AG Debt-to-Equity Related Terms
Roche Holding AG Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Roche Holding AG's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:RO vs LLY, JNJ, ABBV: Debt-to-Equity Comparison
For the Drug Manufacturers - General subindustry, Roche Holding AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roche Holding AG Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Roche Holding AG's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roche Holding AG (XSWX:RO) has a Debt-to-Equity of 0.98 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Roche Holding AG and its competitors. This is near median its historical median of 0.94. Over the past decade, Roche Holding AG's Debt-to-Equity has ranged from 0.42 to 1.33. According to the industry distribution chart, Roche Holding AG ranks #688 out of 809 companies in the Drug Manufacturers industry, placing it in the top 85%.
Is Roche Holding AG's Debt-to-Equity too high?
Roche Holding AG's current Debt-to-Equity of 0.98 is near median its 10-year median of 0.94. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 1.33. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Roche Holding AG's value of 0.98 is 263% above this industry median. Based on the distribution chart, Roche Holding AG ranks #688 out of 809 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Roche Holding AG has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's Debt-to-Equity compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Roche Holding AG ranks #688 out of 809 companies for Debt-to-Equity. This places Roche Holding AG in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Roche Holding AG's value of 0.98 is 263% above this benchmark. Historically, Roche Holding AG's own Debt-to-Equity has ranged from 0.42 to 1.33 over the past decade. While the company's 10-year median is 0.94 vs. the industry median of 0.27, Roche Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roche Holding AG's current Debt-to-Equity of 0.98 is 263% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Roche Holding AG and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roche Holding AG's current Debt-to-Equity is 0.98, which is near median its own 10-year median of 0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:RO) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF269.24, compared to a current price of CHF346.20 — trading 28.6% above its estimated fair value. The current Debt-to-Equity is 0.98, which is near median its 10-year median of 0.94 and 263% above the Drug Manufacturers industry median of 0.27. Roche Holding AG's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Roche Holding AG (XSWX:RO), the current Debt-to-Equity is 0.98 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roche Holding AG (XSWX:RO) Overvalued in 2026?
Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued.
The current stock price of CHF346.20 is trading 28.6% above its estimated GF Value™ of CHF269.24.
GuruFocus considers Roche Holding AG to be Modestly Overvalued.
Key valuation signals for XSWX:RO:
Debt-to-Equity: 0.98 (near median its 10-year median of 0.94)
GF Value™: CHF269.24 vs. price of CHF346.20 (28.6% above fair value)
Industry Position: 263% above the Drug Manufacturers median (#688 of 809)
No single metric tells the full story. See the XSWX:RO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
75GF Score
Get the complete analysis for XSWX:RO
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RO has been successfully added to your 
